These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 37786437)
1. Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma. Gau SY; Chen SL; Chang CS; Tsao TF; Tsai JD Int J Med Sci; 2023; 20(10):1358-1362. PubMed ID: 37786437 [No Abstract] [Full Text] [Related]
2. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Bissler JJ; Franz DN; Frost MD; Belousova E; Bebin EM; Sparagana S; Berkowitz N; Ridolfi A; Kingswood JC Pediatr Nephrol; 2018 Jan; 33(1):101-109. PubMed ID: 28993887 [TBL] [Abstract][Full Text] [Related]
3. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. Franz DN; Budde K; Kingswood JC; Belousova E; Sparagana S; de Vries PJ; Berkowitz N; Ridolfi A; Bissler JJ J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1796-1803. PubMed ID: 29569806 [TBL] [Abstract][Full Text] [Related]
4. Rapamycin and rapalogs for tuberous sclerosis complex. Sasongko TH; Ismail NF; Zabidi-Hussin Z Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011272. PubMed ID: 27409709 [TBL] [Abstract][Full Text] [Related]
5. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Bissler JJ; Budde K; Sauter M; Franz DN; Zonnenberg BA; Frost MD; Belousova E; Berkowitz N; Ridolfi A; Christopher Kingswood J Nephrol Dial Transplant; 2019 Jun; 34(6):1000-1008. PubMed ID: 30053159 [TBL] [Abstract][Full Text] [Related]
6. Everolimus compliance and persistence among tuberous sclerosis complex patients with renal angiomyolipoma or subependymal giant cell astrocytoma. Song X; Said Q; Tran O; Krueger DA; Bissler J Curr Med Res Opin; 2019 Jun; 35(6):1103-1110. PubMed ID: 30550347 [TBL] [Abstract][Full Text] [Related]
7. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1. Kingswood JC; Jozwiak S; Belousova ED; Frost MD; Kuperman RA; Bebin EM; Korf BR; Flamini JR; Kohrman MH; Sparagana SP; Wu JY; Brechenmacher T; Stein K; Berkowitz N; Bissler JJ; Franz DN Nephrol Dial Transplant; 2014 Jun; 29(6):1203-10. PubMed ID: 24729041 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. Cockerell I; Christensen J; Hoei-Hansen CE; Holst L; Grenaa Frederiksen M; Issa-Epe AI; Nedregaard B; Solhoff R; Heimdal K; Johannessen Landmark C; Lund C; Nærland T Orphanet J Rare Dis; 2023 Dec; 18(1):377. PubMed ID: 38042867 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of everolimus on small renal angiomyolipoma in cases of tuberous sclerosis complex-related epilepsy and subependymal giant cell astrocytoma. Hatano T; Yuri Y Asian J Surg; 2023 Mar; 46(3):1236-1237. PubMed ID: 36031512 [No Abstract] [Full Text] [Related]
10. The Efficacy of Everolimus for Facial Angiofibromas in Tuberous Sclerosis Complex Patients Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma. Wei CC; Hsiao YP; Gau SY; Wu YT; Wu CT; Wu MH; Tsai JD Dermatology; 2021; 237(3):444-449. PubMed ID: 33032292 [TBL] [Abstract][Full Text] [Related]
11. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809 [TBL] [Abstract][Full Text] [Related]
12. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex. Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586 [TBL] [Abstract][Full Text] [Related]
13. Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complex. Hatano T; Inaba H; Endo K; Egawa S Int J Urol; 2017 Nov; 24(11):780-785. PubMed ID: 28905429 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan. Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662 [TBL] [Abstract][Full Text] [Related]
15. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization. Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of low-dose everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex. Hatano T; Endo K; Tamari M Int J Clin Oncol; 2021 Jan; 26(1):163-168. PubMed ID: 32990779 [TBL] [Abstract][Full Text] [Related]
17. Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study. Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Belousova E; Frost MD; Sauter M; Brakemeier S; de Vries PJ; Berkowitz N; Voi M; Peyrard S; Budde K PLoS One; 2017; 12(8):e0180939. PubMed ID: 28792952 [TBL] [Abstract][Full Text] [Related]
18. Efficacy, Retention and Tolerability of Everolimus in Patients with Tuberous Sclerosis Complex: A Survey-Based Study on Patients' Perspectives. Willems LM; Rosenow F; Schubert-Bast S; Kurlemann G; Zöllner JP; Bast T; Bertsche A; Bettendorf U; Ebrahimi-Fakhari D; Grau J; Hahn A; Hartmann H; Hertzberg C; Hornemann F; Immisch I; Jacobs J; Klein KM; Klotz KA; Kluger G; Knake S; Knuf M; Marquard K; Mayer T; Meyer S; Muhle H; Müller-Schlüter K; von Podewils F; Ruf S; Sauter M; Schäfer H; Schlump JU; Syrbe S; Thiels C; Trollmann R; Wiemer-Kruel A; Wilken B; Zukunft B; Strzelczyk A CNS Drugs; 2021 Oct; 35(10):1107-1122. PubMed ID: 34275102 [TBL] [Abstract][Full Text] [Related]
19. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Franz DN; Belousova E; Sparagana S; Bebin EM; Frost M; Kuperman R; Witt O; Kohrman MH; Flamini JR; Wu JY; Curatolo P; de Vries PJ; Berkowitz N; Anak O; Niolat J; Jozwiak S Lancet Oncol; 2014 Dec; 15(13):1513-1520. PubMed ID: 25456370 [TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of renal angiomyolipoma associated with tuberous sclerosis complex and the outcome of short-term everolimus therapy. Ni J; Yan F; Qin W; Yu L; Zhang G; Liu F; Yang X; Yang B; Hao C; Wang T; Liu P; Yuan J; Wu G Sci Rep; 2019 Oct; 9(1):14337. PubMed ID: 31586081 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]